Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director | May 28, 2026 | June 01, 2026 |
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | February 07, 2019 | February 13, 2019 |
| Equillium, Inc.EQ · Entity 6560 | Director · CHAIRMAN | May 28, 2026 | May 29, 2026 |
| GERON CORPGERN · Entity 4989 | Director | March 29, 2019 | April 01, 2019 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | May 25, 2017 | May 26, 2017 |
| Vivani Medical, Inc.VANI · Entity 6636 | Director | July 27, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,766 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 11,766 · Balance 11,766 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.
CORCEPT THERAPEUTICS INC
Report date February 07, 2019 · Filed February 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBioBrit LLC | 130,575 |
Reported balance
After 2019-02-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-02-07 · Gift · Disposed 25,000 · Balance 130,575 |
Equillium, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2036-05-27 | Direct | 70,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 70,000 · Balance 70,000 F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
GERON CORP
Report date March 29, 2019 · Filed April 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Commmon StockSEC Table I · non-derivative | IndirectFamily Trust | 51,323 |
Reported balance
After 2019-03-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-03-29 · Grant · Acquired 9,036 · Balance 51,323 F1: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2019 of $1.66 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2019 of $1.66 per share.
ILLUMINA, INC.
Report date May 25, 2017 · Filed May 26, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,324 |
Ending reported balance
After 2017-05-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-05-25 · Exercise / conversion · Acquired 600 · Balance 15,924 F1: The sale was made pursuant to a 10b5-1 plan. Row 2 · 2017-05-25 · Sale · Disposed 300 · Balance 15,624 F1: The sale was made pursuant to a 10b5-1 plan. F2: Weighted average sale price representing 300 shares sold ranging from $172.74 to $173.65 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Row 3 · 2017-05-25 · Sale · Disposed 300 · Balance 15,324 F1: The sale was made pursuant to a 10b5-1 plan. F3: Weighted average sale price representing 300 shares sold ranging from $173.82 to $174.09 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.09 · Expires 2023-05-29 | Direct | 1,600 |
Reported balance
After 2017-05-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-05-25 · Exercise / conversion · Disposed 600 · Balance 1,600 F1: The sale was made pursuant to a 10b5-1 plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was made pursuant to a 10b5-1 plan.
F2: Weighted average sale price representing 300 shares sold ranging from $172.74 to $173.65 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
F3: Weighted average sale price representing 300 shares sold ranging from $173.82 to $174.09 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
Vivani Medical, Inc.
Report date July 27, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2026-07-26 | Direct | 7,965 |
Reported balance
After 2026-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-27 · Grant · Acquired 7,965 · Balance 7,965 F2: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service. F1: The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date.
F2: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 23,548 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-11-08 · Other · Disposed 7,812 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: These shares are held by BioBrit, LLC ("BioBrit"). Mr. Bradbury and his spouse are the trustees and beneficiaries of a trust that is the sole member of BioBrit. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 3,196 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: These shares are held by BioBrit, LLC ("BioBrit"). Mr. Bradbury and his spouse are the trustees and beneficiaries of a trust that is the sole member of BioBrit.
F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Nuvation Bio Inc.
Report date February 10, 2021 · Filed February 27, 2021
Section 16 reporting ended · disclosed 2021-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2021-02-10 transaction · row 1
1 source rowRow 1 · 2021-02-10 · Exercise / conversion · Acquired 25,000 · Balance 25,000 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-10 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2020 Filed Jul 23, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2 | $42.84 | $85.68 |
DisclosureSEC source: 0001447362-20-000155 · wf-form4_159553478080217.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 867,328 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,300 | $42.29 | $97,267.00 |
DisclosureSEC source: 0001447362-20-000155 · wf-form4_159553478080217.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 867,330 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $41.73 to $42.65, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,448 | $41.05 | $59,440.40 |
DisclosureSEC source: 0001447362-20-000155 · wf-form4_159553478080217.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 869,630 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.72 to $41.71, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 08, 2020 Filed Jul 9, 2020 20:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 746 | $41.97 | $31,308.13 |
DisclosureSEC source: 0001447362-20-000142 · wf-form4_159432532049801.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 871,078 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $41.880 to $42.130, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 08, 2020 Filed Jul 9, 2020 20:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,004 | $41.22 | $123,833.89 |
DisclosureSEC source: 0001447362-20-000142 · wf-form4_159432532049801.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 871,824 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $40.840 to $41.830, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,750 | $41.06 | $112,915.00 |
DisclosureSEC source: 0001447362-20-000142 · wf-form4_159432532049801.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 874,828 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $40.680 to $41.560, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,000 | $40.05 | $40,047.00 |
DisclosureSEC source: 0001447362-20-000142 · wf-form4_159432532049801.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 877,578 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $39.640 to $40.635, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 20:57 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 901 | $43.90 | $39,553.90 |
DisclosureSEC source: 0001447362-20-000133 · wf-form4_159285940285572.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 878,578 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $43.59 to $44.27, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 20:57 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,149 | $42.94 | $49,338.06 |
DisclosureSEC source: 0001447362-20-000133 · wf-form4_159285940285572.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 879,479 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $42.58 to $43.50, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 20:57 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,700 | $42.16 | $71,672.00 |
DisclosureSEC source: 0001447362-20-000133 · wf-form4_159285940285572.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 880,628 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $41.57 to $42.52, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:57 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,793 | $42.83 | $76,794.19 |
DisclosureSEC source: 0001447362-20-000133 · wf-form4_159285940285572.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 882,328 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $42.62 to $43.14, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:57 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,557 | $42.10 | $65,549.70 |
DisclosureSEC source: 0001447362-20-000133 · wf-form4_159285940285572.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 884,121 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $41.60 to $42.59, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:57 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 300 | $41.09 | $12,327.00 |
DisclosureSEC source: 0001447362-20-000133 · wf-form4_159285940285572.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 885,678 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $40.50 to $41.48, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:57 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 100 | $38.94 | $3,894.00 |
DisclosureSEC source: 0001447362-20-000133 · wf-form4_159285940285572.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 885,978 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F2 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 727 | $37.79 | $27,475.51 |
DisclosureSEC source: 0001447362-20-000103 · wf-form4_159138754132995.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 886,078 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $37.680 to $37.930, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,023 | $37.31 | $112,776.04 |
DisclosureSEC source: 0001447362-20-000103 · wf-form4_159138754132995.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 886,805 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $36.680 to $37.660, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 16:31 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantCommon Stock · Derivative | 8,000 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001447362-20-000115 · wf-form4_159163386869564.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-06-03 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 13 | $38.30 | $497.84 |
DisclosureSEC source: 0001447362-20-000103 · wf-form4_159138754132995.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 889,828 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,087 | $37.74 | $41,020.12 |
DisclosureSEC source: 0001447362-20-000103 · wf-form4_159138754132995.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 889,841 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $37.280 to $38.245, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,650 | $36.71 | $97,276.20 |
DisclosureSEC source: 0001447362-20-000103 · wf-form4_159138754132995.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 890,928 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $36.190 to $37.170, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| May 28, 2020 Filed May 29, 2020 20:30 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 28,708 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-20-032937 · doc4.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director · Executive Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,708 Underlying: Common Stock · 28,708 shares Expires 2030-05-27 Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 19:05 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,966 | $0.00 Strike: $72.74 | $0.00 |
DisclosureSEC source: 0001104659-20-068536 · tm2021501d7_4.xml · derivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,966 Underlying: Common Stock · 2,966 shares Expires 2030-05-28 F3 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 19:05 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-068536 · tm2021501d7_4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,782 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| May 21, 2020 Filed May 22, 2020 20:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,251 | $37.43 | $84,250.43 |
DisclosureSEC source: 0001447362-20-000076 · wf-form4_159017812288427.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 893,578 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $37.150 to $37.915, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| May 21, 2020 Filed May 22, 2020 20:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,499 | $36.88 | $55,284.62 |
DisclosureSEC source: 0001447362-20-000076 · wf-form4_159017812288427.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 895,829 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $36.140 to $37.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,651 | $37.25 | $61,493.15 |
DisclosureSEC source: 0001447362-20-000076 · wf-form4_159017812288427.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 897,328 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $37.170 to $37.390, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9,599 | $36.84 | $353,646.36 |
DisclosureSEC source: 0001447362-20-000076 · wf-form4_159017812288427.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 898,979 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $36.145 to $37.145, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 23:08 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-060272 · doc4.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2029-12-09 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionConvertible Promissory Note · Derivative | Not disclosed | Not disclosed Strike: $12.80 | $874,537.48 |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · derivative · entry 11 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 71,003 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The principal amount of the Convertible Promissory Note held by the LLC was $874,537.48. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F4 · reported_value: The principal amount of the Convertible Promissory Note held by the LLC was $874,537.48. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F4 · price: The principal amount of the Convertible Promissory Note held by the LLC was $874,537.48. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F4 · derivative.exercise_date: The principal amount of the Convertible Promissory Note held by the LLC was $874,537.48. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F4 · derivative.expiration_date: The principal amount of the Convertible Promissory Note held by the LLC was $874,537.48. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries F Preferred Stock · Derivative | 254,781 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · derivative · entry 10 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 209,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries E-3 Preferred Stock · Derivative | 48,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · derivative · entry 9 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 39,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries E-2 Preferred Stock · Derivative | 54,613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · derivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 44,801 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries E-1 Preferred Stock · Derivative | 168,528 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · derivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 138,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries D Preferred Stock · Derivative | 171,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · derivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 140,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries C Preferred Stock · Derivative | 28,735 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · derivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 23,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries B Preferred Stock · Derivative | 157,059 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · derivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 128,839 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries A Preferred Stock · Derivative | 136,906 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · derivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 0 Underlying: Common Stock · 112,307 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionCommon Stock | 71,003 | $12.80 | $908,838.40 |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 908,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The principal amount of the Convertible Promissory Note held by the LLC was $874,537.48. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 20:29 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionCommon Stock | 837,575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043862 · doc4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 837,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares of Common Stock issued upon conversion of the Preferred Stock were calculated by first aggregating all series of Preferred Stock held by the Reporting Person, in accordance with the terms of the Company's then-effective Certificate of Incorporation. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,174 | $0.00 Strike: $82.25 | $0.00 |
DisclosureSEC source: 0001144204-19-031955 · tv524021_4.xml · derivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Underlying: Common Stock · 2,174 shares Expires 2029-06-20 F3 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-031955 · tv524021_4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,187 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 23:55 UTC | GERON CORP GERN · Entity 4989 | GrantCommmon Stock | 9,036 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-19-000047 · edgar.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 51,323 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2019 of $1.66 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2019 of $1.66 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2019 of $1.66 per share. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 23:15 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001209191-19-010761 · doc4.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 07, 2019 Filed Feb 13, 2019 02:44 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-003384 · doc4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · BioBrit LLC Disclosed balance after: 130,575 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 00:18 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-19-000004 · edgar.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 42,287 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 31, 2018 of $1.00 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 31, 2018 of $1.00 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 31, 2018 of $1.00 per share. Read SEC document |
| October 16, 2018 Filed Oct 16, 2018 21:39 UTC | Equillium, Inc. EQ · Entity 6560 | OtherCommon Stock | 38,796 | $11.20 | $434,515.20 |
DisclosureSEC source: 0001209191-18-055168 · doc4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By BioBrit, LLC Disclosed balance after: 2,969,596 F2 · kind: In connection with the closing of the IPO, a convertible promissory note of the Issuer beneficially owned by the Reporting Person in the principal amount of $409,732.00, plus $24,785.98 accrued interest, automatically converted into shares of the Issuer's common stock at a conversion price of $11.20 per share. F3 · ownership.nature: These securities are held by BioBrit, LLC for which the Reporting Person is the managing member. Read SEC document |
| October 16, 2018 Filed Oct 16, 2018 21:39 UTC | Equillium, Inc. EQ · Entity 6560 | OtherCommon Stock | 9,699 | $11.20 | $108,628.80 |
DisclosureSEC source: 0001209191-18-055168 · doc4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Bradbury Family 2009 Irrevocable Trust Dated September 1, 2009 Disclosed balance after: 742,399 F1 · kind: In connection with the closing of the initial public offering of the Issuer's common stock (the "IPO"), a convertible promissory note of the Issuer beneficially owned by the Reporting Person in the principal amount of $102,433.00, plus $6,196.49 accrued interest, automatically converted into shares of the Issuer's common stock at a conversion price of $11.20 per share. Read SEC document |
| September 28, 2018 Filed Sep 29, 2018 00:00 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 8,523 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-18-000052 · edgar.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 27,287 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 28, 2018 of $1.76 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 28, 2018 of $1.76 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 28, 2018 of $1.76 per share. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 21:42 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000899243-18-023082 · doc4.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-20 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 29, 2018 over a one-year period. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 22:31 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0000886744-18-000040 · edgar.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 18,764 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 29, 2018 of $3.43 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 29, 2018 of $3.43 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 29, 2018 of $3.43 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.